Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.

  title={Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.},
  author={Andres Enriquez and Gregory Y. H. Lip and Adrian M Baranchuk},
  journal={Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology},
  volume={18 7},
In recent years, non-vitamin K oral anticoagulants (NOACs) have emerged as an alternative to warfarin for the prevention and treatment of thrombo-embolic disease. Large randomized trials have demonstrated that these agents, which act by directly targeting thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, and edoxaban), are at least as effective as warfarin, with lower rates of bleeding and fewer interactions with food and drugs. In addition, NOACs have a more predictable anticoagulant… CONTINUE READING